Epstein-Barr virus antibodies don’t predict MS disease progression

A new study suggests that while people with multiple sclerosis (MS) tend to have higher levels of antibodies to the Epstein–Barr virus (EBV), these antibodies do not indicate whether someone’s MS will become more active or worsen over time.

Researchers in the United States followed 187 people with MS and compared them with 50 people without MS. They measured antibodies against two EBV proteins, EBNA1 and VCA. As expected, average antibody levels were higher in the MS group than in the control group. People with relapsing MS had notably higher EBNA1 antibody levels, while VCA levels tended to be lower than in progressive MS, although this trend was not strong.

The key finding is that antibody levels did not track with clinical outcomes. Over more than five years of follow up, neither EBNA1 nor VCA antibody levels were linked to measures of disability such as the Expanded Disability Status Scale, confirmed disability progression, or progression independent of relapse activity. There was also no association with MRI lesion counts, brain volume loss, optic nerve damage, or blood biomarkers of nerve injury. Use of disease modifying therapies did not appear to change EBV antibody levels.

For people living with MS, the takeaway is that EBV antibody tests are unlikely to help predict future disease activity or guide treatment choices at present. Your healthcare team will continue to rely on clinical assessments, MRI scans, and established biomarkers when monitoring MS. Research into EBV and MS is ongoing, and future studies may identify other EBV related markers that provide clearer insights into progression.